Editor’s note: Discover the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center
.
The coronavirus may damage blood marrow cells in patients with extreme COVID-19, according to a brand-new research study released in the journal Science Immunology.
.
Previous research studies have discovered that COVID-19 develops an “overstated” reaction from the body immune system, and for some patients, this might happen in immune cells discovered in bone marrow, the researchers write.
The findings “provide support to the concept that therapeutic methods targeting release of … cells from bone marrow need to be considered in this disease,” they write.
The research team analyzed the immune profiles of 43 hospitalized clients during the peak of the pandemic in the UK. They discovered several shifts in immune signatures, particularly monocytes, which are brand-new immune cells that are launched into the bloodstream from bone marrow.
For most clients with moderate COVID-19, abnormal levels shifted back to regular throughout their healthcare facility stay. In COVID-19 patients with more extreme illness, the monocytes didn’t work effectively.
The scientists weren’t sure whether the monocytes were altered before they were released from the bone marrow or whether they were altered after they entered the blood, according to Reuters
Even still, treatments that prevent the monocytes from being released could reduce the exaggerated immune reaction related to serious COVID-19, the news service reported.
Notably, the immune abnormalities were present before patients were admitted to intensive care, the researchers write, which could imply that medical facilities should start immune treatments soon after admission.
” Dealing with patients early after hospitalization is likely to be most useful, while … immune functions are interfered with,” they compose.
The research study was supported by The Kennedy Trust for Rheumatology Research, The Wellcome Trust, The Wellcome Trust/Royal Society, the Lister Institute, and BBSRC.
.
Sci Immunol. 2020; 5(51): eabd6197 Full text
.
Comments
Post a Comment